United StatesBreaking News

Michael Swanson, chief agriculture economist at Wells Fargo's Agri-Food Institute, said that fruits and vegetables are facing the most pressure from global events, as higher fuel prices and supply chain disruption squeeze both farmers and consumers. Swanson also said that he doesn't expect the protein craze to go away anytime soon, as obesity drugs send consumers looking for higher nutritional value in fewer calories.

Peter Atwater, president at Financial Insyghts and lecturer at William & Mary College, said that the top and bottom of the 'K-shaped economy' have become two vastly different experiences with 'nothing in common' as consumers on the bottom leg of the 'K' feel the daily impact of war fueled inflation and a labor market impacted by AI. Atwater says that the affordability crunch at the bottom of the 'K' will likely result in political turnover in midterm elections this fall.

James Henson, Director of the Texas Politics Project at the University of Texas at Austin said that if the TX GOP primary was going to come down money. Sen. John Cornyn (R-TX) would be "running away" with the race.

Bloomberg's Scott Patterson joins Isabelle Lee and Tim Stenovec on "Bloomberg Crypto." The SEC is delaying a plan to provide broad exemptions for US crypto firms to trade tokenized assets linked to stocks, according to people familiar with the matter.

Bloomberg's Vildana Hajric and Bloomberg Intelligence's James Seyffart join Isabelle Lee and Tim Stenovec on "Bloomberg Crypto." The top US securities regulator is delaying the launch of a wave of novel exchange-traded funds that would let investors wager on events such as elections and economic data as the agency weighs how far the $15 trillion ETF wrapper can stretch.

Heather Conley, Nonresident Senior Fellow at AEI and Former Deputy Assistant Secretary of State for the Bureau of European and Eurasian Affairs says because Iran controls the Strait of Hormuz, they have a strategic advantage.

Jay Ritter, University of Florida emeritus professor and director of the IPO Initiative, known as "Mr. IPO" for his work on initial public offerings, joins Caroline Hyde and Ed Ludlow on "Bloomberg Tech." to discuss SpaceX's IPO. It is set to be "the largest private-sector company ever to go public," for the broader tech IPO landscape, he says.

Merck (NYSE:MRK) announced that its board of directors has formally declared a quarterly dividend of $0.85 per share.

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases.  The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday.  "These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," Dan Skovronsky, Lilly's chief scientific and product officer, said in a statement.  Bloomberg News Health Reporter, Madison Muller, joins Paul Sweeney and Alexis Christoforous on "Bloomberg Intelligence" to analyze what's next for Eli Lilly after agreeing to buy three vaccine developers.

Qualcomm will supply chips to TikTok owner ByteDance for artificial intelligence data centers, according to people familiar with the matter. Ian King helped break the story and he reports on "Bloomberg Tech."

Kyivstar Group (NASDAQ:KYIV) announced the acquisition of six solar power plants in Ukraine’s Lviv region for a total consideration of UAH 3.6 billion (approximately $80.8 million), accelerating the telecommunication firm’s vertical integration into sovereign power generation to mitigate localized infrastructure risks.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) unveiled new clinical data expanding the medical profile of plozasiran, its approved RNA interference (RNAi) therapeutic, demonstrating that the drug can be administered to patients suffering from moderate-to-severe renal impairment or moderate hepatic impairment without necessitating a reduction in dose.